Long-term safety and efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) in subjects with haemophilia A

Haemophilia

Volumn 22, Issue 1, 2016, Pages 72-80

  Nolan, B ^a   Mahlangu, J ^b   Perry, D ^c   Young, G ^d   Liesner, R ^e   Konkle, B ^f   Rangarajan, S ^g   Brown, S ^h   Hanabusa, H ⁱ   Pasi, K J ^j   Pabinger, I ^k   Jackson, S ^l   Cristiano, L M ^m   Li, X ^m   Pierce, G F ^m   Allen, G ^m  

^a OUR LADY S CHILDREN S HOSPITAL   (Ireland)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c ADDENBROOKE S HOSPITAL   (United Kingdom)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^f PUGET SOUND BLOOD CENTER   (United States)

^g BASINGSTOKE AND NORTH HAMPSHIRE HOSPITAL   (United Kingdom)

^h LADY CILENTO CHILDREN S HOSPITAL   (Australia)

ⁱ TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^j QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^k UNIVERSITY OF VIENNA   (Austria)

^l ST PAUL S HOSPITAL   (Canada)

^m BIOGEN   (United States)

more..

Author keywords

Factor VIII; Haemophilia A; Phase 3; Prophylaxis; Recombinant fusion proteins

Indexed keywords

BLOOD CLOTTING FACTOR 8 ANTIBODY; CREATININE; HYBRID PROTEIN; HYDROCHLOROTHIAZIDE; LISINOPRIL; NEUTRALIZING ANTIBODY; RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT FACTOR VIII FC FUSION PROTEIN; TENOFOVIR DISOPROXIL; UNCLASSIFIED DRUG; BLOOD CLOTTING FACTOR 8;

ADVERSE DRUG REACTION; ARTHRALGIA; ARTICLE; BLEEDING; CHILD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONTUSION; COUGHING; CREATININE BLOOD LEVEL; DENTAL CARIES; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG EXPOSURE; DRUG INDUCED HEADACHE; DRUG SAFETY; FALLING; FEMALE; HEAD INJURY; HEMOPHILIA A; HEMOPHILIC ARTHROPATHY; HOT FLUSH; HUMAN; INFLUENZA; LACERATION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; ORAL BLEEDING; PERSONALIZED MEDICINE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROPHYLAXIS; RHINOPHARYNGITIS; SCHOOL CHILD; SIDE EFFECT; THROMBOSIS; UPPER RESPIRATORY TRACT INFECTION; VIRAL UPPER RESPIRATORY TRACT INFECTION; VIRUS INFECTION; VOMITING; CLINICAL TRIAL; COMPLICATION; PERIOPERATIVE PERIOD; SAFETY;

CHILD; CHILD, PRESCHOOL; FACTOR VIII; FEMALE; HEMOPHILIA A; HEMORRHAGE; HUMANS; MALE; PERIOPERATIVE CARE; RECOMBINANT FUSION PROTEINS; SAFETY;

EID: 84959046658     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12766     Document Type: Article

References (15)

1. Mannucci PM, Tuddenham EG. The hemophilias-from royal genes to gene therapy. N Engl J Med 2001; 344: 1773-9.
2. National Hemophilia Foundation. Medical and Scientific Advisory Council (MASAC) recommendation concerning prophylaxis (regular administration of clotting factor concentrate to prevent bleeding), 2007. Available at http://www.hemophilia.org/NHFWeb/MainPgs/MainNHF.aspx?menuid=57&contentid=1007. Accessed May 28, 2015
3. Manco-Johnson MJ, Abshire TC, Shapiro AD et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357: 535-44.
4. Bjorkman S, Oh M, Spotts G et al. Population pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics to age and body weight. Blood 2012; 119: 612-8.
5. Hacker MR, Geraghty S, Manco-Johnson M. Barriers to compliance with prophylaxis therapy in haemophilia. Haemophilia 2001; 7: 392-6.
6. Zappa S, McDaniel M, Marandola J, Allen G. Treatment trends for haemophilia A and haemophilia B in the United States: results from the 2010 practice patterns survey. Haemophilia 2012; 18: e140-53.
7. Fogarty PF. Biological rationale for new drugs in the bleeding disorders pipeline. Hematology Am Soc Hematol Educ Program 2011; 2011: 397-404.
8. Dumont JA, Liu T, Low SC et al. Prolonged activity of a recombinant factor VIII-Fc fusion protein in hemophilia A mice and dogs. Blood 2012; 119: 3024-30.
9. Peters RT, Toby G, Lu Q et al. Biochemical and functional characterization of a recombinant monomeric factor VIII-Fc fusion protein. J Thromb Haemost 2013; 11: 132-41.
10. Shapiro AD, Ragni MV, Valentino LA et al. Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients. Blood 2012; 119: 666-72.
11. Lillicrap D. Improvements in factor concentrates. Curr Opin Hematol 2010; 17: 393-7.
12. Rath T, Baker K, Dumont JA et al. Fc-fusion proteins and FcRn: structural insights for longer lasting and more effective therapeutics. Crit Rev Biotechnol 2013: 1-20; Early Online.
13. Mahlangu J, Powell JS, Ragni MV et al. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood 2014; 123: 317-25.
14. Young G, Mahlangu J, Kulkarni R et al. Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A. J Thromb Haemost 2015; 13: 967-77.
15. Shapiro AD, Ragni MV, Kulkarni R et al. Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels. J Thromb Haemost 2014; 12: 1788-800.